Financial results - NOROPHARMA CONSULTING SRL

Financial Summary - Noropharma Consulting Srl
Unique identification code: 36104630
Registration number: J13/1329/2016
Nace: 4690
Sales - Ron
29.992
Net Profit - Ron
3.528
Employees
1
Open Account
Company Noropharma Consulting Srl with Fiscal Code 36104630 recorded a turnover of 2024 of 29.992, with a net profit of 3.528 and having an average number of employees of 1. The company operates in the field of Comerţ cu ridicata nespecializat having the NACE code 4690.
Sales - Ron

Sales, Profit, Employees, Total Income, Financial Results - Noropharma Consulting Srl

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Sales - EUR - 0 12.795 11.504 14.157 15.568 17.348 16.707 24.088 29.992
Total Income - EUR - 145 13.416 11.964 14.471 15.892 17.770 22.230 25.079 31.208
Total Expenses - EUR - 1.966 12.146 13.911 26.616 13.555 15.749 21.727 23.827 26.713
Gross Profit/Loss - EUR - -1.822 1.270 -1.947 -12.145 2.337 2.021 502 1.251 4.495
Net Profit/Loss - EUR - -1.822 887 -2.288 -12.570 1.900 1.492 -133 591 3.528
Employees - 1 1 1 1 1 1 1 1 1
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded. In the last year of activity, the sales increased by 25.2%, from 24.088 euro in the year 2023, to 29.992 euro in 2024. The Net Profit increased by 2.940 euro, from 591 euro in 2023, to 3.528 in the last year.
Sales - Ron
Net Profit - Ron
Employees

Check the financial reports for the company - Noropharma Consulting Srl

Rating financiar

Financial Rating -
NOROPHARMA CONSULTING SRL

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Financial Rating
Limite de plata

Payment Limits -
Noropharma Consulting Srl

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Noropharma Consulting Srl

It determines the risk of insolvency based on the submitted accounting balance.

Insolvency Probability
Rapoarte financiare

Financial Reports -
Noropharma Consulting Srl

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Noropharma Consulting Srl - CUI 36104630

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Fixed Assets - 0 0 0 11.475 8.443 6.027 4.616 4.137 1.525
Current Assets - 40.538 40.892 36.700 12.496 16.037 19.352 21.165 17.340 21.578
Inventories - 32.668 21.595 20.090 4.591 5.413 8.633 4.181 6.869 2.144
Receivables - 223 5.140 2.421 2.955 2.146 804 662 1.404 550
Cash - 7.647 14.156 14.189 4.950 8.479 9.915 16.322 9.066 18.884
Shareholders Funds - 9.312 10.042 7.569 -5.147 -3.150 -1.587 -1.725 -1.129 2.405
Social Capital - 11.134 10.945 10.745 10.537 10.337 10.108 10.139 10.108 10.052
Debts - 31.226 30.850 29.130 29.118 27.630 26.966 27.506 22.606 20.699
Income in Advance - 0 0 0 0 0 0 0 0 0
Exchange rate - RON 4.9743 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445
Main CAEN "4690 - 4690"
CAEN Financial Year 4690
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 21.578 euro in 2024 which includes Inventories of 2.144 euro, Receivables of 550 euro and cash availability of 18.884 euro.
The company's Equity was valued at 2.405 euro, while total Liabilities amounted to 20.699 euro. Equity increased by 3.528 euro, from -1.129 euro in 2023, to 2.405 in 2024.

Risk Reports Prices

Reviews - Noropharma Consulting Srl

Comments - Noropharma Consulting Srl

Similar services useful for checking companies and business development.

SellNet

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Databases

Export in excel files the data of the companies selected according to the desired criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.